Sundeep Khosla

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3801729/sundeep-khosla-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

463 papers	45,995 citations	106 h-index	202 g-index
505 ext. papers	52,128 ext. citations	7.6 avg, IF	7.74 L-index

#	Paper	IF	Citations
463	Osteoporosis and bone loss **2022**, 335-361		
462	Orally-active, clinically-translatable senolytics restore Klotho in mice and humans.. *EBioMedicine*, **2022**, 103912	8.8	1
461	Bone marrow adiposity in models of radiation- and aging-related bone loss is dependent on cellular senescence.. *Journal of Bone and Mineral Research*, **2022**,	6.3	1
460	Targeted clearance of p21- but not p16-positive senescent cells prevents radiation-induced osteoporosis and increased marrow adiposity.. *Aging Cell*, **2022**, e13602	9.9	3
459	Skeletal Aging. *Mayo Clinic Proceedings*, **2022**, 97, 1194-1208	6.4	2
458	Bone microarchitecture phenotypes identified in older adults are associated with different levels of osteoporotic fracture risk.. *Journal of Bone and Mineral Research*, **2021**,	6.3	2
457	Modulation of fracture healing by the transient accumulation of senescent cells. *ELife*, **2021**, 10,	8.9	2
456	Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. *EMBO Journal*, **2021**, 40, e106048	13	26
455	Risk of bone fractures after the diagnosis of adrenal adenomas: a population-based cohort study. *European Journal of Endocrinology*, **2021**, 184, 597-606	6.5	3
454	Global and Spatial Compartmental Interrelationships of Bone Density, Microstructure, Geometry and Biomechanics in the Distal Radius in a CollesPFracture Study Using HR-pQCT. *Frontiers in Endocrinology*, **2021**, 12, 568454	5.7	0
453	Opportunistic application of phantom-less calibration methods for fracture risk prediction using QCT/FEA. *European Radiology*, **2021**, 31, 9428-9435	8	3
452	Senolytics reduce coronavirus-related mortality in old mice. *Science*, **2021**, 373,	33.3	60
451	Establishment of normative biometric data for body composition based on computed tomography in a North American cohort. *Clinical Nutrition*, **2021**, 40, 2435-2442	5.9	0
450	Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span. *Annual Review of Pharmacology and Toxicology*, **2021**, 61, 779-803	17.9	52
449	Estrogen deficiency and the pathogenesis of osteoporosis **2021**, 773-797		0
448	Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. *European Heart Journal*, **2021**, 42, 1595-1605	9.5	25
447	Senescent cells exacerbate chronic inflammation and contribute to periodontal disease progression in old mice. *Journal of Periodontology*, **2021**, 92, 1483-1495	4.6	6

446	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. *Journal of Bone and Mineral Research*, **2021**, 36, 236-243	6.3	4
445	Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. *Journal of the American Geriatrics Society*, **2021**, 69, 3023-3033	5.6	9
444	Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. *Nature Reviews Endocrinology*, **2021**, 17, 685-697	15.2	6
443	Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. *Journal of Bone and Mineral Research*, **2021**,	6.3	2
442	The role of senolytics in osteoporosis and other skeletal pathologies. *Mechanisms of Ageing and Development*, **2021**, 199, 111565	5.6	4
441	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. *Journal of Orthopaedic Trauma*, **2020**, 34, e125-e141	3.1	6
440	Managing fragility fractures during the COVID-19 pandemic. *Nature Reviews Endocrinology*, **2020**, 16, 467-468	15.2	27
439	Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	13
438	Male mice with elevated C-type natriuretic peptide-dependent guanylyl cyclase-B activity have increased osteoblasts, bone mass and bone strength. *Bone*, **2020**, 135, 115320	4.7	7
437	The Impact of Mild Autonomous Cortisol Secretion on Bone Turnover Markers. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	8
436	The role of cellular senescence in ageing and endocrine disease. *Nature Reviews Endocrinology*, **2020**, 16, 263-275	15.2	133
435	Estrogen Versus FSH Effects on Bone Metabolism: Evidence From Interventional Human Studies. *Endocrinology*, **2020**, 161,	4.8	7
434	Posterior single-stepping thresholds are prospectively related to falls in older women. *Aging Clinical and Experimental Research*, **2020**, 32, 2507-2515	4.8	5
433	Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss. *Journal of Bone and Mineral Research*, **2020**, 35, 1119-1131	6.3	40
432	Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. *JCI Insight*, **2020**, 5,	9.9	25
431	SUN-LB68 Advanced Glycation Endproducts Are Associated With Worse Bone Material Strength in Older Adults With and Without Type 2 Diabetes. *Journal of the Endocrine Society*, **2020**, 4,	0.4	1
430	The microbiome adds to the complexity of parathyroid hormone action on bone. *Journal of Clinical Investigation*, **2020**, 130, 1615-1617	15.9	1
429	SUN-381 Cortical Porosity Is Associated with Peripheral Small Vessel Disease in Adult Patients with Type 2 Diabetes. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78

428	Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. *Nature Communications*, **2020**, 11, 87	17.4	53
427	LPS-induced premature osteocyte senescence: Implications in inflammatory alveolar bone loss and periodontal disease pathogenesis. *Bone*, **2020**, 132, 115220	4.7	25
426	Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records. *Journal of Biomedical Informatics*, **2020**, 102, 103364	10.2	24
425	Estrogens and progestins **2020**, 827-837		
424	Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 894-902	18.1	40
423	Comparison of Vertebral and Femoral Strength Between White and Asian Adults Using Finite Element Analysis of Computed Tomography Scans. *Journal of Bone and Mineral Research*, **2020**, 35, 2345-2354	6.3	5
422	Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 672-682	18.1	40
421	Osteocyte Cellular Senescence. *Current Osteoporosis Reports*, **2020**, 18, 559-567	5.4	4
420	Periodontal Disease and Senescent Cells: New Players for an Old Oral Health Problem?. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
419	Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study. *European Journal of Endocrinology*, **2020**, 183, 181-189	6.5	3
418	Biology and Clinical Aspects of Estrogen Action on Bone **2020**, 524-532		
417	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. *Journal of Bone and Mineral Research*, **2020**, 35, 36-52	6.3	63
416	Reducing Senescent Cell Burden in Aging and Disease. *Trends in Molecular Medicine*, **2020**, 26, 630-638	11.5	47
415	Development and Application of Mass Spectroscopy Assays for N(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes. *journal of applied laboratory medicine, The*, **2020**, 5, 558-568	2	5
414	Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMedicine*, **2019**, 47, 446-456	8.8	356
413	Personalising osteoporosis treatment for patients at high risk of fracture. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 739-741	18.1	5
412	Cellular senescence in bone. *Bone*, **2019**, 121, 121-133	4.7	68
411	A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention". *Journal of Bone and Mineral Research*, **2019**, 34, 1549-1551	6.3	4

410	Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans. *Journal of Bone and Mineral Research*, **2019**, 34, 1407-1418	6.3	35
409	Circulating Osteogenic Progenitor Cells in Mild, Moderate, and Severe Aortic Valve Stenosis. *Mayo Clinic Proceedings*, **2019**, 94, 652-659	6.4	3
408	Virtual supersampling as post-processing step preserves the trabecular bone morphometry in human peripheral quantitative computed tomography scans. *PLoS ONE*, **2019**, 14, e0212280	3.7	
407	Translation to Practice: Accelerating the Cycle of Innovation to Impact. *Mayo Clinic Proceedings*, **2019**, 94, 490-499	6.4	0
406	Skeletal considerations in the medical treatment of transgender people. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 893-895	18.1	2
405	Increased Cortical Porosity and Reduced Trabecular Density Are Not Necessarily Synonymous With Bone Loss and Microstructural Deterioration. *JBMR Plus*, **2019**, 3, e10078	3.9	16
404	Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials. *Clinical Endocrinology*, **2019**, 90, 293-300	3.4	16
403	miR-219a-5p Regulates Ror During Osteoblast Differentiation and in Age-related Bone Loss. *Journal of Bone and Mineral Research*, **2019**, 34, 135-144	6.3	24
402	Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 34-43	18.1	139
401	Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). *Journal of Bone and Mineral Research*, **2018**, 33, 1291-1301	6.3	46
400	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. *Journal of Bone and Mineral Research*, **2018**, 33, 634-642	6.3	30
399	Evaluation of cross-sectional and longitudinal changes in volumetric bone mineral density in postmenopausal women using single- versus dual-energy quantitative computed tomography. *Bone* , **2018**, 112, 145-152	4.7	17
398	Net ankle quasi-stiffness is influenced by walking speed but not age for older adult women. *Gait and Posture*, **2018**, 62, 311-316	2.6	11
397	The trabecular effect: A population-based longitudinal study on age and sex differences in bone mineral density and vertebral load bearing capacity. *Clinical Biomechanics*, **2018**, 55, 73-78	2.2	8
396	Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 1282-1290	5.6	70
395	Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments. *Bone*, **2018**, 111, 36-43	4.7	8
394	Regulation of Bone Metabolism by Sex Steroids. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	89
393	Factors associated with proximal femur fracture determined in a large cadaveric cohort. *Bone*, **2018** , 116, 196-202	4.7	15

392	Sympathetic β-adrenergic signaling contributes to regulation of human bone metabolism. *Journal of Clinical Investigation*, **2018**, 128, 4832-4842	15.9	44
391	Senolytics improve physical function and increase lifespan in old age. *Nature Medicine*, **2018**, 24, 1246-1256	36.5	776
390	Advancing the Science of Healthcare Service Delivery: The NHLBI Corporate Healthcare LeadersP Panel. *Global Heart*, **2018**, 13, 339-345	2.9	3
389	Sex Steroids and the Pathogenesis of Osteoporosis **2018**, 412-418		1
388	Aging, Obesity, and the Incidence of Diverticulitis: A Population-Based Study. *Mayo Clinic Proceedings*, **2018**, 93, 1256-1265	6.4	22
387	Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 Diabetes. *Journal of Osteoporosis*, **2018**, 2018, 7153021	2.8	4
386	The relationships between compensatory stepping thresholds and measures of gait, standing postural control, strength, and balance confidence in older women. *Gait and Posture*, **2018**, 65, 74-80	2.6	11
385	Osteoprotection Through the Deletion of the Transcription Factor Rorβ in Mice. *Journal of Bone and Mineral Research*, **2018**, 33, 720-731	6.3	11
384	Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis. *Stem Cell Reports*, **2017**, 8, 373-386	8	40
383	The comparability of HR-pQCT bone measurements is improved by scanning anatomically standardized regions. *Osteoporosis International*, **2017**, 28, 2115-2128	5.3	28
382	Clinical, cellular, microscopic, and ultrastructural studies of a case of fibrogenesis imperfecta ossium. *Bone Research*, **2017**, 5, 16057	13.3	5
381	Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. *Journal of Bone and Mineral Research*, **2017**, 32, 424-430	6.3	91
380	The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA. *Osteoporosis International*, **2017**, 28, 1225-1232	5.3	64
379	Hormonal and systemic regulation of sclerostin. *Bone*, **2017**, 96, 8-17	4.7	43
378	Bone diseases: Romosozumab - on track or derailed?. *Nature Reviews Endocrinology*, **2017**, 13, 697-698	15.2	18
377	New hope for symptom management during natural and iatrogenic menopause transitions. *Biology of Reproduction*, **2017**, 97, 177-178	3.9	4
376	Targeting cellular senescence prevents age-related bone loss in mice. *Nature Medicine*, **2017**, 23, 1072-1079	36.5	464
375	Fracture Incidence and Characteristics in Young Adults Aged 18 to 49 Years: A Population-Based Study. *Journal of Bone and Mineral Research*, **2017**, 32, 2347-2354	6.3	23

374	The circumstances, orientations, and impact locations of falls in community-dwelling older women. *Archives of Gerontology and Geriatrics*, **2017**, 73, 240-247	4	35
373	Response to Stoecker et al. *Journal of Bone and Mineral Research*, **2017**, 32, 1388	6.3	
372	Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. *Endocrine Reviews*, **2017**, 38, 325-350	27.2	114
371	Osteoporosis treatment: recent developments and ongoing challenges. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 898-907	18.1	315
370	Statistical Parametric Mapping of HR-pQCT Images: A Tool for Population-Based Local Comparisons of Micro-Scale Bone Features. *Annals of Biomedical Engineering*, **2017**, 45, 949-962	4.7	8
369	Circulating osteogenic endothelial progenitor cell counts: new biomarker for the severity of coronary artery disease. *International Journal of Cardiology*, **2017**, 227, 833-839	3.2	16
368	The Limited Clinical Utility of Testosterone, Estradiol, and Sex Hormone Binding Globulin Measurements in the Prediction of Fracture Risk and Bone Loss in Older Men. *Journal of Bone and Mineral Research*, **2017**, 32, 633-640	6.3	27
367	Operator variability in scan positioning is a major component of HR-pQCT precision error and is reduced by standardized training. *Osteoporosis International*, **2017**, 28, 245-257	5.3	24
366	Determinants of bone strength and quality in diabetes mellitus in humans. *Bone*, **2016**, 82, 28-34	4.7	109
365	Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. *Diabetes* , **2016**, 65, 1757-66	0.9	93
364	Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease. *Cell Metabolism*, **2016**, 23, 1207-1215	24.6	139
363	Voxel size dependency, reproducibility and sensitivity of an in vivo bone loading estimation algorithm. *Journal of the Royal Society Interface*, **2016**, 13, 20150991	4.1	15
362	Osteoclast TGF-Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation. *Journal of Bone and Mineral Research*, **2016**, 31, 76-85	6.3	50
361	Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. *Journal of Bone and Mineral Research*, **2016**, 31, 65-75	6.3	89
360	Comprehensive Assessment of Osteoporosis and Bone Fragility with CT Colonography. *Radiology*, **2016**, 278, 172-80	20.5	42
359	A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy. *Injury Prevention*, **2016**, 22, 297-301	3.2	3
358	Bone Quality in Type 2 Diabetes Mellitus **2016**, 211-224		2
357	Identification of Senescent Cells in the Bone Microenvironment. *Journal of Bone and Mineral Research*, **2016**, 31, 1920-1929	6.3	214

356	Microarchitecture and Peripheral BMD are Impaired in Postmenopausal White Women With Fracture Independently of Total Hip T-Score: An International Multicenter Study. *Journal of Bone and Mineral Research*, **2016**, 31, 1158-66	6.3	59
355	Deletion of Estrogen Receptor Beta in Osteoprogenitor Cells Increases Trabecular but Not Cortical Bone Mass in Female Mice. *Journal of Bone and Mineral Research*, **2016**, 31, 606-14	6.3	28
354	Hdac3 Deficiency Increases Marrow Adiposity and Induces Lipid Storage and Glucocorticoid Metabolism in Osteochondroprogenitor Cells. *Journal of Bone and Mineral Research*, **2016**, 31, 116-28	6.3	44
353	Can vitamin D metabolite measurements facilitate a "treat-to-target" paradigm to guide vitamin D supplementation?. *Osteoporosis International*, **2015**, 26, 1655-60	5.3	18
352	The AchillesPheel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell*, **2015**, 14, 644-58	9.9	987
351	Global transcriptional profiling using RNA sequencing and DNA methylation patterns in highly enriched mesenchymal cells from young versus elderly women. *Bone*, **2015**, 76, 49-57	4.7	27
350	Clinical Use of Quantitative Computed Tomography-Based Advanced Techniques in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part III. *Journal of Clinical Densitometry*, **2015**, 18, 393-407	3.5	69
349	Clinical Use of Quantitative Computed Tomography-Based Finite Element Analysis of the Hip and Spine in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part II. *Journal of Clinical Densitometry*, **2015**, 18, 359-92	3.5	83
348	Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. *International Journal of Cardiology*, **2015**, 181, 57-64	3.2	24
347	Parathyroid Hormone in the Pathophysiology of Osteoporosis **2015**, 827-835		
346	New Insights Into Androgen and Estrogen Receptor Regulation of the Male Skeleton. *Journal of Bone and Mineral Research*, **2015**, 30, 1134-7	6.3	39
345	Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. *Skeletal Muscle*, **2015**, 5, 21	5.1	54
344	Response to Wnt Signaling Pathways. *Journal of Bone and Mineral Research*, **2015**, 30, 2135-6	6.3	1
343	Ability of circulating human hematopoietic lineage negative cells to support hematopoiesis. *Journal of Cellular Biochemistry*, **2015**, 116, 58-66	4.7	2
342	Regarding "True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo". *Journal of Bone and Mineral Research*, **2015**, 30, 2325-6	6.3	8
341	Skeletal changes through the lifespan--from growth to senescence. *Nature Reviews Endocrinology*, **2015**, 11, 513-21	15.2	77
340	Clinical Use of Quantitative Computed Tomography (QCT) of the Hip in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part I. *Journal of Clinical Densitometry*, **2015**, 18, 338-58	3.5	70
339	Effects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing. *PLoS ONE*, **2015**, 10, e0138347	3.7	43

338	Automatic multi-parametric quantification of the proximal femur with quantitative computed tomography. *Quantitative Imaging in Medicine and Surgery*, **2015**, 5, 552-68	3.6	22
337	The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. *Osteoporosis International*, **2014**, 25, 1439-43	5.3	331
336	Isolation and characterization of human osteoblasts from needle biopsies without in vitro culture. *Osteoporosis International*, **2014**, 25, 887-95	5.3	17
335	Seeding Open Innovation Drug Discovery and Translational Collaborations to Leverage Government Funding: A Case Study of Strategic Partnership between Sanford-Burnham and Mayo Clinic **2014**, 451-486		
334	Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. *Journal of Bone and Mineral Research*, **2014**, 29, 1356-62	6.3	136
333	Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E81-8	5.6	56
332	Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. *Bone*, **2014**, 59, 1-6	4.7	79
331	Diminished bone strength is observed in adult women and men who sustained a mild trauma distal forearm fracture during childhood. *Journal of Bone and Mineral Research*, **2014**, 29, 2193-202	6.3	19
330	Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. *Molecular Endocrinology*, **2014**, 28, 1740-51		37
329	Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. *American Journal of Gastroenterology*, **2014**, 109, 401-8	0.7	42
328	Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. *Vascular Health and Risk Management*, **2014**, 10, 533-8	4.4	25
327	Dissection of estrogen receptor alpha signaling pathways in osteoblasts using RNA-sequencing. *PLoS ONE*, **2014**, 9, e95987	3.7	20
326	Novel anthropomorphic hip phantom corrects systemic interscanner differences in proximal femoral vBMD. *Physics in Medicine and Biology*, **2014**, 59, 7819-34	3.8	9
325	Body composition during childhood and adolescence: relations to bone strength and microstructure. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 4641-8	5.6	38
324	Bone strength and structural deficits in children and adolescents with a distal forearm fracture resulting from mild trauma. *Journal of Bone and Mineral Research*, **2014**, 29, 590-9	6.3	57
323	Priscilla Chen 1944–2013. *Journal of Bone and Mineral Research*, **2014**, 29, 517-517	6.3	
322	In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. *Journal of Bone and Mineral Research*, **2014**, 29, 787-95	6.3	338
321	Mutual enhancement of differentiation of osteoblasts and osteocytes occurs through direct cell-cell contact. *Journal of Cellular Biochemistry*, **2014**, 115, 2039-44	4.7	15

320	Osteoporosis detection in postmenopausal women using axial transmission multi-frequency bone ultrasonometer: clinical findings. *Ultrasonics*, **2014**, 54, 1170-7	3.5	19
319	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. *Lancet Oncology, The*, **2014**, 15, 474-82	21.7	38
318	Trends in fracture incidence: a population-based study over 20 years. *Journal of Bone and Mineral Research*, **2014**, 29, 581-9	6.3	196
317	Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss **2013**, 1113-1136		4
316	TGF-induces Wnt10b in osteoclasts from female mice to enhance coupling to osteoblasts. *Endocrinology*, **2013**, 154, 3745-52	4.8	57
315	Polyphenol-rich cranberry juice has a neutral effect on endothelial function but decreases the fraction of osteocalcin-expressing endothelial progenitor cells. *European Journal of Nutrition*, **2013**, 52, 289-96	5.2	54
314	Identification of Ror targets in cultured osteoblasts and in human bone. *Biochemical and Biophysical Research Communications*, **2013**, 440, 768-73	3.4	11
313	The Role of Sex Steroids in the Pathogenesis of Osteoporosis **2013**, 367-375		5
312	Relationship of adiposity to bone volumetric density and microstructure in men and women across the adult lifespan. *Bone*, **2013**, 55, 119-25	4.7	49
311	Transforming growth factor beta 1 induces CXCL16 and leukemia inhibitory factor expression in osteoclasts to modulate migration of osteoblast progenitors. *Bone*, **2013**, 57, 68-75	4.7	52
310	Longitudinal changes in lumbar bone mineral density distribution may increase the risk of wedge fractures. *Clinical Biomechanics*, **2013**, 28, 10-4	2.2	12
309	Structural patterns of the proximal femur in relation to age and hip fracture risk in women. *Bone*, **2013**, 57, 290-9	4.7	34
308	Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women. *Mayo Clinic Proceedings*, **2013**, 88, 46-55	6.4	30
307	Three-dimensional structural analysis of the proximal femur in an age-stratified sample of women. *Bone*, **2013**, 55, 179-88	4.7	27
306	Pathogenesis of age-related bone loss in humans. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2013**, 68, 1226-35	6.4	133
305	Osteonecrosis of the Jaw and Atypical Femoral Fractures **2013**, 1873-1908		2
304	Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways. *Journal of Biological Chemistry*, **2013**, 288, 5398-406	5.4	58
303	Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength. *Journal of Medical Devices, Transactions of the ASME*, **2013**, 7, 410051-410056	1.3	48

302	Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E249-57	5.6	33
301	Improved fracture risk assessment based on nonlinear micro-finite element simulations from HRpQCT images at the distal radius. *Journal of Bone and Mineral Research*, **2013**, 28, 2601-8	6.3	35
300	A distal forearm fracture in childhood is associated with an increased risk for future fragility fractures in adult men, but not women. *Journal of Bone and Mineral Research*, **2013**, 28, 1751-9	6.3	31
299	Multicenter precision of cortical and trabecular bone quality measures assessed by high-resolution peripheral quantitative computed tomography. *Journal of Bone and Mineral Research*, **2013**, 28, 524-36	6.3	89
298	Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. *Journal of Cellular Biochemistry*, **2013**, 114, 1901-1907	4.7	49
297	Proximal femoral density distribution and structure in relation to age and hip fracture risk in women. *Journal of Bone and Mineral Research*, **2013**, 28, 537-46	6.3	58
296	Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes. *Arthritis Research and Therapy*, **2013**, 15, R179	5.7	74
295	Sclerostin levels during growth in children. *Osteoporosis International*, **2012**, 23, 1123-30	5.3	58
294	Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women. *Osteoporosis International*, **2012**, 23, 155-62	5.3	35
293	Emerging role of circulating calcifying cells in the bone-vascular axis. *Circulation*, **2012**, 125, 2772-81	16.7	66
292	Benefits and risks of bisphosphonate therapy for osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2272-82	5.6	190
291	Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. *Lancet Oncology, The*, **2012**, 13, 275-84	21.7	90
290	Characterization of mesenchymal progenitor cells isolated from human bone marrow by negative selection. *Bone*, **2012**, 50, 804-10	4.7	36
289	Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men. *Journal of Bone and Mineral Research*, **2012**, 27, 2159-69	6.3	79
288	Male osteoporosis. *Endocrinology and Metabolism Clinics of North America*, **2012**, 41, 629-41	5.5	53
287	Estrogen and the skeleton. *Trends in Endocrinology and Metabolism*, **2012**, 23, 576-81	8.8	394
286	Role of circulating osteogenic progenitor cells in calcific aortic stenosis. *Journal of the American College of Cardiology*, **2012**, 60, 1945-53	15.1	59
285	Potential Extensions of the US FRAX Algorithm. *Journal of Osteoporosis*, **2012**, 2012, 528790	2.8	13

284	Sex- and age-related differences in bone microarchitecture in men relative to women assessed by high-resolution peripheral quantitative computed tomography. *Journal of Osteoporosis*, **2012**, 2012, 129760	2.8	21
283	Relationship of age to bone microstructure independent of areal bone mineral density. *Journal of Bone and Mineral Research*, **2012**, 27, 637-44	6.3	101
282	Examination of nuclear receptor expression in osteoblasts reveals Rorβ as an important regulator of osteogenesis. *Journal of Bone and Mineral Research*, **2012**, 27, 891-901	6.3	30
281	Odanacatib: location and timing are everything. *Journal of Bone and Mineral Research*, **2012**, 27, 506-8	6.3	25
280	Fracture risk in women with breast cancer: a population-based study. *Journal of Bone and Mineral Research*, **2012**, 27, 1196-205	6.3	31
279	Assessing fracture risk using gradient boosting machine (GBM) models. *Journal of Bone and Mineral Research*, **2012**, 27, 1397-404	6.3	33
278	A DNA binding mutation in estrogen receptor-α leads to suppression of Wnt signaling via β-catenin destabilization in osteoblasts. *Journal of Cellular Biochemistry*, **2012**, 113, 2248-55	4.7	12
277	TGF-β mediates suppression of adipogenesis by estradiol through connective tissue growth factor induction. *Endocrinology*, **2012**, 153, 254-63	4.8	30
276	Age-dependent renal cortical microvascular loss in female mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2012**, 302, E979-86	6	20
275	Examination of ERβ signaling pathways in bone of mutant mouse models reveals the importance of ERE-dependent signaling. *Endocrinology*, **2012**, 153, 5325-33	4.8	16
274	Patients with an HbA1c in the prediabetic and diabetic range have higher numbers of circulating cells with osteogenic and endothelial progenitor cell markers. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 4761-8	5.6	31
273	Insulin-mediated FFA suppression is associated with triglyceridemia and insulin sensitivity independent of adiposity. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 4130-8	5.6	16
272	Osteocalcin positive CD133+/CD34-/KDR+ progenitor cells as an independent marker for unstable atherosclerosis. *European Heart Journal*, **2012**, 33, 2963-9	9.5	60
271	Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 4219-27	5.6	45
270	Better tools for assessing osteoporosis. *Journal of Clinical Investigation*, **2012**, 122, 4323-4	15.9	11
269	Osteoporosis update from the 2010 santa fe bone symposium. *Journal of Clinical Densitometry*, **2011**, 14, 1-21	3.5	8
268	The Role of the Immune System in the Development of Osteoporosis **2011**, 269-299		1
267	Effects of physiological variations in circulating insulin levels on bone turnover in humans. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1450-5	5.6	53

266	Distinct effects of loss of classical estrogen receptor signaling versus complete deletion of estrogen receptor alpha on bone. *Bone*, **2011**, 49, 208-16	4.7	24
265	Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. *Bone*, **2011**, 49, 202-7	4.7	67
264	Effects of intermittent parathyroid hormone treatment on osteoprogenitor cells in postmenopausal women. *Bone*, **2011**, 49, 349-55	4.7	28
263	Emerging therapeutic opportunities for skeletal restoration. *Nature Reviews Drug Discovery*, **2011**, 10, 141-56	64.1	108
262	Osteoporosis: now and the future. *Lancet, The*, **2011**, 377, 1276-87	40	1443
261	What accounts for rib fractures in older adults?. *Journal of Osteoporosis*, **2011**, 2011, 457591	2.8	22
260	Human immunodeficiency virus envelope protein Gp120 induces proliferation but not apoptosis in osteoblasts at physiologic concentrations. *PLoS ONE*, **2011**, 6, e24876	3.7	5
259	Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS. *Blood*, **2011**, 118, 6529-34	2.2	55
258	The bone and beyond: a shift in calcium. *Nature Medicine*, **2011**, 17, 430-1	50.5	25
257	Robust QCT/FEA models of proximal femur stiffness and fracture load during a sideways fall on the hip. *Annals of Biomedical Engineering*, **2011**, 39, 742-55	4.7	174
256	Trabecular bone deficits among Vietnamese immigrants. *Osteoporosis International*, **2011**, 22, 1627-31	5.3	2
255	Determinants of forearm strength in postmenopausal women. *Osteoporosis International*, **2011**, 22, 3047-54	5.3	6
254	Towards a diagnostic and therapeutic consensus in male osteoporosis. *Osteoporosis International*, **2011**, 22, 2789-98	5.3	94
253	Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow. *Journal of Orthopaedic Research*, **2011**, 29, 1804-11	3.8	21
252	Regulation of circulating sclerostin levels by sex steroids in women and in men. *Journal of Bone and Mineral Research*, **2011**, 26, 27-34	6.3	172
251	Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. *Journal of Bone and Mineral Research*, **2011**, 26, 373-9	6.3	263
250	The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. *Journal of Bone and Mineral Research*, **2011**, 26, 441-51	6.3	235
249	Association of hip strength estimates by finite-element analysis with fractures in women and men. *Journal of Bone and Mineral Research*, **2011**, 26, 1593-600	6.3	92

248	Fracture risk in men with prostate cancer: a population-based study. *Journal of Bone and Mineral Research*, **2011**, 26, 1808-15	6.3	32
247	Relationship of testosterone and osteocalcin levels during growth. *Journal of Bone and Mineral Research*, **2011**, 26, 2212-6	6.3	65
246	Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover. *Journal of Bone and Mineral Research*, **2011**, 26, 2548-51	6.3	18
245	Is vitamin D a determinant of muscle mass and strength?. *Journal of Bone and Mineral Research*, **2011**, 26, 2860-71	6.3	84
244	Wnt10b activates the Wnt, notch, and NFB pathways in U2OS osteosarcoma cells. *Journal of Cellular Biochemistry*, **2011**, 112, 1392-402	4.7	39
243	The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. *Endocrinology*, **2011**, 152, 4691-705	4.8	76
242	What do we tell our patients about calcium and vitamin D supplementation?. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 69-71	5.6	9
241	Is nitroglycerin a novel and inexpensive treatment for osteoporosis?. *JAMA - Journal of the American Medical Association*, **2011**, 305, 826-7	27.4	13
240	Nonoxidative free fatty acid disposal is greater in young women than men. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 541-7	5.6	40
239	Fat tissue, aging, and cellular senescence. *Aging Cell*, **2010**, 9, 667-84	9.9	645
238	Effects of estrogen and testosterone on resting energy expenditure in older men. *Obesity*, **2010**, 18, 2392-4	8	9
237	Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 5063-8	5.6	74
236	Update in male osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3-10	5.6	129
235	Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. *European Heart Journal*, **2010**, 31, 2909-14	9.5	58
234	Pathogenesis of Osteoporosis. *Translational Endocrinology & Metabolism*, **2010**, 1, 55-86		13
233	Placebo-controlled trials in osteoporosis--proceeding with caution. *New England Journal of Medicine*, **2010**, 363, 1365-7; discussion e22	59.2	15
232	Update on estrogens and the skeleton. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3569-77	5.6	121
231	Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 5056-62	5.6	211

230	The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. *Endocrinology*, **2010**, 151, 3675-85	4.8	80
229	Physiology of bone loss. *Radiologic Clinics of North America*, **2010**, 48, 483-95	2.3	162
228	Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women. *Bone*, **2010**, 47, 83-92	4.7	32
227	Human embryonic stem cell-derived CD34+ cells function as MSC progenitor cells. *Bone*, **2010**, 47, 718-28	4.7	49
226	Female reproductive system and bone. *Archives of Biochemistry and Biophysics*, **2010**, 503, 118-28	4.1	110
225	Age-dependence of femoral strength in white women and men. *Journal of Bone and Mineral Research*, **2010**, 25, 994-1001	6.3	87
224	Relation of serum serotonin levels to bone density and structural parameters in women. *Journal of Bone and Mineral Research*, **2010**, 25, 415-22	6.3	71
223	Assessing forearm fracture risk in postmenopausal women. *Osteoporosis International*, **2010**, 21, 1161-9	5.3	95
222	Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. *Journal of Bone and Mineral Research*, **2010**, 25, 2438-46	6.3	40
221	Relation of vertebral deformities to bone density, structure, and strength. *Journal of Bone and Mineral Research*, **2010**, 25, 1922-30	6.3	80
220	Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair. *Stem Cells*, **2010**, 28, 2124-8	5.8	67
219	Modulators of androgen and estrogen receptor activity. *Critical Reviews in Eukaryotic Gene Expression*, **2010**, 20, 275-94	1.3	6
218	The Role of Wnt-10b in Osteoblast Development. *FASEB Journal*, **2010**, 24, 888.1	0.9	
217	Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. *Journal of Biological Chemistry*, **2009**, 284, 18767-77	5.4	21
216	Bisphosphonate associated osteonecrosis of the jaw. *Journal of Rheumatology*, **2009**, 36, 478-90	4.1	131
215	Increasing options for the treatment of osteoporosis. *New England Journal of Medicine*, **2009**, 361, 818-20	39.2	62
214	For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. *Kidney International*, **2009**, 75, 1071-8	9.9	79
213	Fatty acid metabolism in the elderly: effects of dehydroepiandrosterone and testosterone replacement in hormonally deficient men and women. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 3414-23	5.6	27

212	Higher muscle protein synthesis in women than men across the lifespan, and failure of androgen administration to amend age-related decrements. *FASEB Journal*, **2009**, 23, 631-41	0.9	71
211	Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. *Osteoporosis International*, **2009**, 20, 761-9	5.3	13
210	Bone structure at the distal radius during adolescent growth. *Journal of Bone and Mineral Research*, **2009**, 24, 1033-42	6.3	198
209	Assessing the true impact of recurrent fractures on fracture risk. *Journal of Bone and Mineral Research*, **2009**, 24, 1512-4	6.3	1
208	Androgens and bone. *Steroids*, **2009**, 74, 296-305	2.8	161
207	Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases. *Mayo Clinic Proceedings*, **2009**, 84, 893-902	6.4	142
206	New selective estrogen and androgen receptor modulators. *Current Opinion in Rheumatology*, **2009**, 21, 374-9	5.3	30
205	DISORDERS OF CALCIUM METABOLISM AND BONE MINERALIZATION **2009**, 587-609		1
204	Mesenchymal stem cells for bone repair and metabolic bone diseases. *Mayo Clinic Proceedings*, **2009**, 84, 893-902	6.4	73
203	Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. *Journal of Oral and Maxillofacial Surgery*, **2008**, 66, 1320-1; author reply 1321-2	1.8	44
202	Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. *Journal of the American College of Cardiology*, **2008**, 52, 1314-25	15.1	137
201	The skeletal response to estrogen is impaired in female but not in male steroid receptor coactivator (SRC)-1 knock out mice. *Bone*, **2008**, 42, 414-21	4.7	19
200	Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. *Bone*, **2008**, 43, 414-7	4.7	33
199	Use of renal function measurements for assessing fracture risk in postmenopausal women. *Mayo Clinic Proceedings*, **2008**, 83, 1231-9	6.4	10
198	Bisphosphonates: mechanism of action and role in clinical practice. *Mayo Clinic Proceedings*, **2008**, 83, 1032-45	6.4	829
197	Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. *Endocrine Reviews*, **2008**, 29, 155-92	27.2	582
196	Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20764-9	11.5	387
195	Bone growth and turnover in progesterone receptor knockout mice. *Endocrinology*, **2008**, 149, 2383-90	4.8	33

194	Osteoporosis in men. *Endocrine Reviews*, **2008**, 29, 441-64	27.2	278
193	Insulin-like growth factor binding protein-2: a novel regulator of skeletal gender differences?. *Endocrinology*, **2008**, 149, 2048-50	4.8	1
192	A bone structural basis for fracture risk in diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 4804-9	5.6	109
191	Estrogen receptor beta isoform-specific induction of transforming growth factor beta-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. *Molecular Endocrinology*, **2008**, 22, 1579-95		42
190	Building bone to reverse osteoporosis and repair fractures. *Journal of Clinical Investigation*, **2008**, 118, 421-8	15.9	282
189	Estrogen Effects on Bone in the Male Skeleton **2008**, 1801-1818		1
188	A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. *Journal of Bone and Mineral Research*, **2008**, 23, 205-14	6.3	383
187	Regulation of bone turnover by sex steroids in men. *Journal of Bone and Mineral Research*, **2008**, 23, 705-14	6.3	31
186	Cost-effective osteoporosis treatment thresholds: the United States perspective. *Osteoporosis International*, **2008**, 19, 437-47	5.3	332
185	Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. *Osteoporosis International*, **2008**, 19, 449-58	5.3	317
184	Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. *Osteoporosis International*, **2008**, 19, 1323-30	5.3	145
183	Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density. *Osteoporosis International*, **2008**, 19, 1465-71	5.3	64
182	Skeletal stem/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. *Journal of Cellular Biochemistry*, **2008**, 103, 393-400	4.7	55
181	Loss of ERE binding activity by estrogen receptor-alpha alters basal and estrogen-stimulated bone-related gene expression by osteoblastic cells. *Journal of Cellular Biochemistry*, **2008**, 103, 896-907	4.7	19
180	Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. *Journal of Bone and Mineral Research*, **2008**, 23, 1106-17	6.3	33
179	Fracture risk in type 2 diabetes: update of a population-based study. *Journal of Bone and Mineral Research*, **2008**, 23, 1334-42	6.3	278
178	Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. *Journal of Bone and Mineral Research*, **2008**, 23, 1601-12	6.3	39
177	Estrogen and fracture risk in men. *Journal of Bone and Mineral Research*, **2008**, 23, 1548-51	6.3	34

176	Estrogen, Bone Homeostasis, and Osteoporosis **2008**, 1011-1039		3
175	Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. *Journal of Rheumatology*, **2008**, 35, 1391-7	4.1	111
174	Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. *Diabetes Care*, **2007**, 30, 1972-8	14.6	74
173	Re: "The 3.6 kb DNA fragment from the rat Col1a1 gene promoter drives the expression of genes in both osteoblast and osteoclast lineage cells" by Boban et al. (Bone 39:1302-1312, 2006). *Bone*, **2007**, 40, 1671-2; author reply 1673-4	4.7	1
172	Clinical practice. Osteopenia. *New England Journal of Medicine*, **2007**, 356, 2293-300	59.2	70
171	Are the endocrine societyÞs clinical practice guidelines on androgen therapy in women misguided? A commentary-response. *Journal of Sexual Medicine*, **2007**, 4, 1782-3; author reply 1784-5	1.1	6
170	Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. *Journal of Bone and Mineral Research*, **2007**, 22, 724-9	6.3	165
169	High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. *Journal of Bone and Mineral Research*, **2007**, 22, 799-807	6.3	52
168	Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. *Journal of Bone and Mineral Research*, **2007**, 22, 1442-8	6.3	156
167	Structural determinants of vertebral fracture risk. *Journal of Bone and Mineral Research*, **2007**, 22, 1885-92	6.3	159
166	Two years of treatment with dehydroepiandrosterone does not improve insulin secretion, insulin action, or postprandial glucose turnover in elderly men or women. *Diabetes*, **2007**, 56, 753-66	0.9	47
165	Effects of testosterone and estradiol on cutaneous vasodilation during local warming in older men. *American Journal of Physiology - Endocrinology and Metabolism*, **2007**, 293, E1426-9	6	12
164	Effects of loss of classical estrogen response element signaling on bone in male mice. *Endocrinology*, **2007**, 148, 1902-10	4.8	28
163	High-trauma fractures and bone mineral density. *JAMA - Journal of the American Medical Association* , **2007**, 298, 2418-9	27.4	2
162	Characterization of circulating osteoblast lineage cells in humans. *Bone*, **2007**, 40, 1370-7	4.7	120
161	Estrogen and the death of osteoclasts: A fascinating story. *BoneKEy Osteovision*, **2007**, 4, 267-272		3
160	Remodeling and vascular spaces in bone. *Journal of Bone and Mineral Research*, **2007**, 22, 1-6	6.3	121
159	Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 885-91	5.6	98

158	Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 1848-54	5.6	88
157	Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene: roles of AF1 and enhancer elements. *Journal of Biological Chemistry*, **2006**, 281, 28596-604	5.4	22
156	Androgen therapy in women: an Endocrine Society Clinical Practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 3697-710	5.6	247
155	DHEA in elderly women and DHEA or testosterone in elderly men. *New England Journal of Medicine*, **2006**, 355, 1647-59	59.2	442
154	Long-term fracture risk among women with proven endometriosis. *Fertility and Sterility*, **2006**, 86, 1576-83	4.8	4
153	Estrogen receptor beta: the antimechanostat?. *Bone*, **2006**, 38, 289; author reply 290	4.7	2
152	Circulating cells with osteogenic potential. *Annals of the New York Academy of Sciences*, **2006**, 1068, 489-97	0.5	65
151	Age- and sex-specific differences in the factor of risk for vertebral fracture: a population-based study using QCT. *Journal of Bone and Mineral Research*, **2006**, 21, 1475-82	6.3	118
150	Does reduced skeletal loading account for age-related bone loss?. *Journal of Bone and Mineral Research*, **2006**, 21, 1847-55	6.3	43
149	The classical estrogen receptor transcriptional pathway. *Clinical Reviews in Bone and Mineral Metabolism*, **2006**, 4, 129-140	2.5	
148	Bone fragility in men--where are we?. *Osteoporosis International*, **2006**, 17, 1577-83	5.3	92
147	Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. *Journal of Bone and Mineral Research*, **2006**, 21, 171-7	6.3	290
146	Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. *Journal of Bone and Mineral Research*, **2006**, 21, 124-31	6.3	440
145	Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures. *Journal of Bone and Mineral Research*, **2006**, 21, 315-23	6.3	99
144	Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 5096-103	5.6	66
143	Pathophysiology of age-related bone loss and osteoporosis. *Endocrinology and Metabolism Clinics of North America*, **2005**, 34, 1015-30, xi	5.5	224
142	Mechanisms of sex steroid effects on bone. *Biochemical and Biophysical Research Communications*, **2005**, 328, 688-96	3.4	295
141	Circulating osteoblast-lineage cells in humans. *New England Journal of Medicine*, **2005**, 352, 1959-66	59.2	332

140	Evaluation of a prediction model for long-term fracture risk. *Journal of Bone and Mineral Research*, **2005**, 20, 551-6	6.3	22
139	Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. *Journal of Bone and Mineral Research*, **2005**, 20, 730-40	6.3	115
138	Potential role of pancreatic and enteric hormones in regulating bone turnover. *Journal of Bone and Mineral Research*, **2005**, 20, 1497-506	6.3	68
137	Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. *Journal of Bone and Mineral Research*, **2005**, 20, 1992-2001	6.3	62
136	The role of the immune system in the pathophysiology of osteoporosis. *Immunological Reviews*, **2005**, 208, 207-27	11.3	263
135	Bone marrow stromal cells express two distinct splice variants of ER-alpha that are regulated by estrogen. *Journal of Cellular Biochemistry*, **2005**, 94, 88-97	4.7	11
134	Contributions of bone density and structure to fracture risk assessment in men and women. *Osteoporosis International*, **2005**, 16, 460-7	5.3	91
133	Osteoporosis assessment by whole body region vs. site-specific DXA. *Osteoporosis International*, **2005**, 16, 1558-64	5.3	36
132	A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 1953-60	5.6	8
131	Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. *Molecular Endocrinology* , **2005**, 19, 1555-68		118
130	Magic bullets to kill nasty osteoclasts. *Endocrinology*, **2005**, 146, 3233-4	4.8	4
129	Potential Anabolic Effects of Androgens on Bone. *Mayo Clinic Proceedings*, **2004**, 79, S14-S18	6.4	7
128	Relationship of estrogen receptor genotypes to bone mineral density and to rates of bone loss in men. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1808-16	5.6	60
127	Dose-response of estrogen on bone versus the uterus in ovariectomized mice. *European Journal of Endocrinology*, **2004**, 151, 503-10	6.5	66
126	Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. *Experimental Hematology*, **2004**, 32, 351-9	3.1	20
125	A potentially deleterious role of IGFBP-2 on bone density in aging men and women. *Journal of Bone and Mineral Research*, **2004**, 19, 1075-83	6.3	59
124	Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. *Journal of Bone and Mineral Research*, **2004**, 19, 1945-54	6.3	643
123	Role of hormonal changes in the pathogenesis of osteoporosis in men. *Calcified Tissue International*, **2004**, 75, 110-3	3.9	29

122	Osteoporosis in men--consensus is premature. *Calcified Tissue International*, **2004**, 75, 120-2	3.9	35
121	A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. *Journal of Cellular Biochemistry*, **2004**, 93, 1107-14	4.7	17
120	Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. *Endocrinology*, **2004**, 145, 913-21	4.8	67
119	Fracture risk in monoclonal gammopathy of undetermined significance. *Journal of Bone and Mineral Research*, **2004**, 19, 25-30	6.3	121
118	System for the analysis of whole-bone strength from helical CT images **2004**,		22
117	The Role of Androgens and Estrogens in the Male Skeleton **2004**, 1021-1032		
116	Incidence of childhood distal forearm fractures over 30 years: a population-based study. *JAMA - Journal of the American Medical Association*, **2003**, 290, 1479-85	27.4	338
115	Parathyroid hormone plus alendronate--a combination that does not add up. *New England Journal of Medicine*, **2003**, 349, 1277-9	59.2	62
114	Androgens, estrogens, and bone turnover in men. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 2352; author reply 2352-3	5.6	13
113	Insulin-like growth factor (IGF)-II/IGF-binding proteins in constitutionally tall children. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1912-3; author reply 1913	5.6	0
112	Effect of estrogen replacement therapy on parathyroid hormone secretion in elderly postmenopausal women. *Menopause*, **2003**, 10, 165-71	2.5	17
111	Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. *Journal of Bone and Mineral Research*, **2003**, 18, 213-21	6.3	177
110	Fracture risk after bilateral oophorectomy in elderly women. *Journal of Bone and Mineral Research*, **2003**, 18, 900-5	6.3	91
109	Surrogates for fracture endpoints in clinical trials. *Journal of Bone and Mineral Research*, **2003**, 18, 1146-9	6.3	28
108	Role of parathyroid hormone in mediating age-related changes in bone resorption in men. *Osteoporosis International*, **2003**, 14, 631-6	5.3	21
107	Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. *Osteoporosis International*, **2003**, 14, 728-33	5.3	66
106	Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. *Journal of Cellular Biochemistry*, **2003**, 89, 180-90	4.7	171
105	Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta. *Journal of Cellular Biochemistry*, **2003**, 89, 633-46	4.7	96

104	Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. *Journal of Cellular Biochemistry*, **2003**, 90, 315-26	4.7	130
103	Fracture risk following bilateral orchiectomy. *Journal of Urology*, **2003**, 169, 1747-50	2.5	125
102	The role of estrogens in men and androgens in women. *Endocrinology and Metabolism Clinics of North America*, **2003**, 32, 195-218	5.5	32
101	Estrogen, selective estrogen receptor modulators and now mechanism-specific ligands of the estrogen or androgen receptor?. *Trends in Pharmacological Sciences*, **2003**, 24, 261-3	13.2	10
100	Role of extracellular matrix in insulin-like growth factor (IGF) binding protein-2 regulation of IGF-II action in normal human osteoblasts. *Growth Hormone and IGF Research*, **2003**, 13, 328-35	2	40
99	Mutual antagonism of estrogen receptors alpha and beta and their preferred interactions with steroid receptor coactivators in human osteoblastic cell lines. *Journal of Endocrinology*, **2003**, 176, 349-57	4.7	46
98	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. *Journal of Clinical Investigation*, **2003**, 111, 1221-30	15.9	257
97	Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. *Journal of Clinical Investigation*, **2003**, 111, 1221-1230	15.9	524
96	The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. *Calcified Tissue International*, **2002**, 71, 437-46	3.9	51
95	Correlates of osteoprotegerin levels in women and men. *Osteoporosis International*, **2002**, 13, 394-9	5.3	160
94	Oestrogen, bones and men: when testosterone just isnR enough. *Clinical Endocrinology*, **2002**, 56, 291-3	3.4	14
93	Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. *Journal of Bone and Mineral Research*, **2002**, 17, 172-8	6.3	173
92	Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. *Journal of Bone and Mineral Research*, **2002**, 17, 580-92	6.3	36
91	Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 3867-70	5.6	26
90	Clinical review 144: Estrogen and the male skeleton. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1443-50	5.6	244
89	Leptin-central or peripheral to the regulation of bone metabolism?. *Endocrinology*, **2002**, 143, 4161-4	4.8	46
88	Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1550-4	5.6	149
87	Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. *European Journal of Endocrinology*, **2002**, 147, 269-73	6.5	54

86	Sex steroids and the construction and conservation of the adult skeleton. *Endocrine Reviews*, **2002**, 23, 279-302	27.2	1268
85	Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. *Growth Hormone and IGF Research*, **2002**, 12, 178-83	2	59
84	Secondary osteoporosis and the risk of distal forearm fractures in men and women. *Bone*, **2002**, 31, 119-25	4.7	34
83	AuthorB Response: Effect of Estrogen Versus Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4009-4009	5.6	1
82	Estrogen Effects on Bone in the Male Skeleton **2002**, 1467-1476		4
81	Fracture risk in primary hyperparathyroidism. *Journal of Bone and Mineral Research*, **2002**, 17 Suppl 2, N103-7	6.3	19
80	Estrogens and bone health in men. *Calcified Tissue International*, **2001**, 69, 189-92	3.9	68
79	Regulation of osteoclastogenesis and RANK expression by TGF-beta1. *Journal of Cellular Biochemistry*, **2001**, 83, 320-5	4.7	93
78	Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. *Journal of Cellular Biochemistry*, **2001**, 83, 448-62	4.7	68
77	Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. *Journal of Bone and Mineral Research*, **2001**, 16, 2118-25	6.3	86
76	Leptin reduces ovariectomy-induced bone loss in rats. *Endocrinology*, **2001**, 142, 3546-53	4.8	236
75	Minireview: the OPG/RANKL/RANK system. *Endocrinology*, **2001**, 142, 5050-5	4.8	1071
74	Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. *Biochemical and Biophysical Research Communications*, **2001**, 280, 334-9	3.4	180
73	Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. *Bone*, **2001**, 29, 114-20	4.7	218
72	Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 3555-61	5.6	420
71	The Type I/Type II Model for Involutional Osteoporosis **2001**, 49-58		14
70	Androgens and Androgenic Progestins **2001**, 709-723		
69	Parathyroid Function in the Normal Aging Process **2001**, 835-842		2

68	Cytokine-specific induction of the TGF-beta inducible early gene (TIEG): regulation by specific members of the TGF-beta family. *Journal of Cellular Biochemistry*, **2000**, 78, 380-90	4.7	40
67	The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *Journal of Bone and Mineral Research*, **2000**, 15, 2-12	6.3	861
66	Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men. *Osteoporosis International*, **2000**, 11, 977-83	5.3	79
65	Epidemiology of Sarcopenia. *Mayo Clinic Proceedings*, **2000**, 75, S10-S13	6.4	63
64	Primary Osteoporosis in Men: Role of Sex Steroid Deficiency. *Mayo Clinic Proceedings*, **2000**, 75, S46-S50	6.4	13
63	The Effects of Androgens on Osteoblast Function In Vitro. *Mayo Clinic Proceedings*, **2000**, 75, S51-S54	6.4	3
62	Senile Osteoporosis **2000**, 225-236		
61	The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. *Endocrinology*, **2000**, 141, 4768-76	4.8	230
60	Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. *Metabolism: Clinical and Experimental*, **2000**, 49, 1278-84	12.7	148
59	Fractures following thyroidectomy in women: a population-based cohort study. *Bone*, **2000**, 27, 695-700	4.7	22
58	Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. *Journal of Hepatology*, **2000**, 33, 878-82	13.4	64
57	Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. *Journal of Clinical Investigation*, **2000**, 106, 1553-60	15.9	537
56	Relationship of Intestinal Calcium Absorption to 1,25-Dihydroxyvitamin D [1,25(OH)2D] Levels in Young Versus Elderly Women: Evidence for Age-Related Intestinal Resistance to 1,25(OH)2D Action. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 4023-4027	5.6	95
55	Immunoradiometric Assay for Intact Human Osteocalcin(1-49) without Cross-Reactivity to Breakdown Products. *Clinical Chemistry*, **1999**, 45, 526-531	5.5	9
54	Response of bipotential human marrow stromal cells to insulin-like growth factors: effect on binding protein production, proliferation, and commitment to osteoblasts and adipocytes. *Endocrinology*, **1999**, 140, 5036-44	4.8	72
53	Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. *Endocrinology*, **1999**, 140, 5579-86	4.8	75
52	The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. *Molecular Endocrinology*, **1999**, 13, 819-28		195
51	Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. *Endocrinology*, **1999**, 140, 4367-70	4.8	529

50	Androgen effects on bone metabolism: recent progress and controversies. *European Journal of Endocrinology*, **1999**, 140, 271-86	6.5	96
49	Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. *Endocrinology*, **1999**, 140, 4382-9	4.8	582
48	Primary hyperparathyroidism and the risk of fracture: a population-based study. *Journal of Bone and Mineral Research*, **1999**, 14, 1700-7	6.3	277
47	Osteology: further debate. *Journal of Bone and Mineral Research*, **1999**, 14, 1017	6.3	
46	The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. *Journal of Bone and Mineral Research*, **1999**, 14, 1330-7	6.3	56
45	Secondary osteoporosis and the risk of vertebral deformities in women. *Bone*, **1999**, 24, 49-55	4.7	56
44	Fracture risk after surgery for peptic ulcer disease: a population-based cohort study. *Bone*, **1999**, 25, 61-7	4.7	35
43	Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. *Bone*, **1999**, 25, 255-9	4.7	518
42	The assembly of the adult skeleton during growth and maturation: implications for senile osteoporosis. *Journal of Clinical Investigation*, **1999**, 104, 671-2	15.9	38
41	Estrogens and Bone Health **1999**, 275-298		
40	Reply : unitary model of osteoporosis revisited. *Journal of Bone and Mineral Research*, **1998**, 13, 1955	6.3	2
39	A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. *Journal of Bone and Mineral Research*, **1998**, 13, 763-73	6.3	782
38	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. *Journal of Cellular Biochemistry*, **1998**, 71, 96-108	4.7	42
37	Fracture risk among patients with urolithiasis: a population-based cohort study. *Kidney International*, **1998**, 53, 459-64	9.9	114
36	Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2266-74	5.6	918
35	Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. *Biochemical and Biophysical Research Communications*, **1998**, 250, 776-81	3.4	261
34	Survival after the diagnosis of hyperparathyroidism: a population-based study. *American Journal of Medicine*, **1998**, 104, 115-22	2.4	210
33	Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 751-6	5.6	69

32	Effects of the Circadian Variation in Serum Cortisol on Markers of Bone Turnover and Calcium Homeostasis in Normal Postmenopausal Women. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 751-756	5.6	64
31	A Defect in Renal Calcium Conservation May Contribute to the Pathogenesis of Postmenopausal Osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 1916-1920	5.6	25
30	Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estrogen. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2266-2274	5.6	621
29	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line **1998**, 71, 96		1
28	Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 1522-7	5.6	182
27	Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. *Mayo Clinic Proceedings*, **1997**, 72, 430-6	6.4	34
26	Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. *American Journal of Medicine*, **1997**, 103, 70-3	2.4	26
25	Is familial hyperparathyroidism a unique disease?. *Surgery*, **1997**, 122, 1028-33	3.6	28
24	Relationship of bone turnover to bone density and fractures. *Journal of Bone and Mineral Research*, **1997**, 12, 1083-91	6.3	255
23	Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene. *Journal of Cellular Biochemistry*, **1997**, 66, 542-51	4.7	16
22	Idiopathic Osteoporosis--Is the Osteoblast To Blame?. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 2792-2794	5.6	28
21	Relationship between body composition and bone mass in women. *Journal of Bone and Mineral Research*, **1996**, 11, 857-63	6.3	220
20	Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. *Kidney International*, **1996**, 50, 1663-71	9.9	55
19	Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 513-518	5.6	43
18	Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 1699-1703	5.6	154
17	Role of biochemical markers in assessment of osteoporosis. *Acta Orthopaedica*, **1995**, 66, 14-18		3
16	Treatment options for osteoporosis. *Mayo Clinic Proceedings*, **1995**, 70, 978-82	6.4	16
15	Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. *Journal of Bone and Mineral Research*, **1994**, 9, 1313-8	6.3	79

14	Epidemiology and clinical features of osteoporosis in young individuals. *Bone*, **1994**, 15, 551-5	4.7	138
13	Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the RET proto-oncogene. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 78, 1261-1264	5.6	21
12	Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 79, 211-216	5.6	50
11	Circulating cytokine levels in osteoporotic and normal women. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 79, 707-711	5.6	69
10	Muscle strength in osteoporotic versus normal women. *Osteoporosis International*, **1993**, 3, 8-12	5.3	81
9	Expression of a potential metastasis suppressor gene (nm23) in thyroid neoplasms. *World Journal of Surgery*, **1993**, 17, 615-20; discussion 620-1	3.3	13
8	Clinical performance of parathyroid hormone immunometric assays. *Mayo Clinic Proceedings*, **1992**, 67, 637-45	6.4	67
7	Parathyroid hormone-related peptide in lactation and in umbilical cord blood. *Mayo Clinic Proceedings*, **1990**, 65, 1408-14	6.4	52
6	Nucleotide sequence of cloned cDNAs encoding chicken preproparathyroid hormone. *Journal of Bone and Mineral Research*, **1988**, 3, 689-98	6.3	40
5	Autoimmune hemolytic anemia with both cold and warm autoantibodies. *JAMA - Journal of the American Medical Association*, **1985**, 254, 1175-6	27.4	4
4	beta-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin. *Biochemistry*, **1980**, 19, 2895-901	3.2	218
3	Minireview: The OPG/RANKL/RANK System		329
2	ST-V-Net: incorporating shape prior into convolutional neural networks for proximal femur segmentation. *Complex & Intelligent Systems*,1	7.1	1
1	Chapter 41. Role of Sex Steroids in the Pathogenesis of Osteoporosis208-213		3